Drug Profile
Tetanus vaccine - Zydus Lifesciences
Latest Information Update: 21 Mar 2022
Price :
$50
*
At a glance
- Originator Cadila Healthcare
- Developer Zydus Lifesciences
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Tetanus
Most Recent Events
- 21 Aug 2017 Cadila Healthcare completes a phase II/III trial in Tetanus (In volunteers, In children, In adolescents, In adults) in India (IM) (CTRI2015-05-005740)